BioLineRx Ltd (BLRX NASDAQ) stock market data APIs
$4.5343
0.1(2.2%)
as of July 3, 2025
Try our APIs with
free plan!
BioLineRx Ltd Financial Data Overview
Price chart is built with
Anychart
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Prev. Close
4.5343
Open
4.6308
High
4.5893
Low
4.4061
52 wk Range
2.3001-35.6
Market Cap
17 154 K
Shares Outstanding
3 721 K
Revenue
22 340 K
EPS
-1.5006
Beta
0.901
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BioLineRx Ltd data using free add-ons & libraries
Get BioLineRx Ltd Fundamental Data
BioLineRx Ltd Fundamental data includes:
- Net Revenue: 22 340 K
- EBITDA: -14 000 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-27
- EPS/Forecast: -0.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BioLineRx Ltd News
New
BioLineRx stock maintains buy rating at H.C. Wainwright on cancer data
H.C. Wainwright reiterated its buy rating and $26.00 price target on BioLineRx (NASDAQ:BLRX), a biotech company currently trading at $4.67, following the company’s presentation of full data from the...
BioLineRx upgraded to Buy from Hold at JonesResearch
JonesResearch upgraded BioLineRx (BLRX) to Buy from Hold with a $12 price target The company announced new pilot phase data from the investigator-initiated Phase II combination trial of motixafortide ...
BioLineRx Reports Promising Motixafortide Combo Data In PDAC Ahead Of ASCO 2025
(RTTNews) - BioLineRx Ltd. (BLRX), a clinical-stage biopharmaceutical company, announced on Friday that updated results from the pilot phase of its Phase 2 CheMo4METPANC trial demonstrated promising c...
3 Tech Stocks That Wall Street Loves More Than Nvidia
The future of the U.S. economy appears to be at a pivotal juncture as the Federal Reserve maintains interest rates at a 22-year high, with the possibility of further tightening on the horizon. Despite...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
